Kit Simpson to Reverse Transcriptase Inhibitors
This is a "connection" page, showing publications Kit Simpson has written about Reverse Transcriptase Inhibitors.
Connection Strength
1.747
-
Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors. HIV Med. 2014 Sep; 15(8):488-98.
Score: 0.455
-
Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden. AIDS Care. 2014 Apr; 26(4):466-75.
Score: 0.442
-
Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review. Health Qual Life Outcomes. 2013 Oct 03; 11:164.
Score: 0.441
-
The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manag Care. 1998 Jul; 4(7):1004-12.
Score: 0.153
-
Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. AIDS Res Hum Retroviruses. 2014 Aug; 30(8):753-68.
Score: 0.116
-
Cost-effectiveness of maternal treatment to prevent perinatal hepatitis B virus transmission. Obstet Gynecol. 2011 Sep; 118(3):655-662.
Score: 0.095
-
Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program. J Acquir Immune Defic Syndr. 2000 Apr 01; 23(4):302-13.
Score: 0.043